Skip to main content

Rare genetic variants potentially involved in ovarian hyperstimulation syndrome

Abstract

Purpose

We aim to investigate whether there is a genetic predisposition in women who developed ovarian hyperstimulation syndrome (OHSS) after GnRH antagonist protocol with GnRH agonist trigger and freeze-all approach.

Methods

Four patients with OHSS after GnRH agonist trigger and freeze-all approach were gathered from the worldwide patient population. These patients were analyzed through Whole Exome Sequencing. In this study known causes of OHSS were investigated and new causes present in at least two individuals were searched for.

Results

In the first part of the study, we evaluated the presence of mutations in genes already known to be involved in OHSS. In PGR and TP53, heterozygous alterations were detected. PGR is predicted to be involved in progesterone resistance with a recessive inheritance pattern and is, therefore, not considered as being causal. The consequences of the variant detected in TP53 currently remain unknown. In part 2 of the study, we assessed the clinical significance of variants in genes previously not linked to OHSS. We especially focused on genes with variants present in ≥ 2 patients. Two patients have variants in the FLT4 gene. Mutations in this gene are linked to hereditary lymphedema, but no link to OHSS has been described.

Conclusions

Defining a genetic predisposition for OHSS is essential in view of prevention. In this study, a potential link between the FLT4 gene and OHSS has been suggested. Future functional studies are essential to define a more precise involvement of the detected variants in the development of OHSS.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9:77–96.

    Article  CAS  PubMed  Google Scholar 

  2. Soares SR, Amols MH, Hudson SBA, et al. Etiology of OHSS and use of dopamine agonists. Fertil Steril. 2012;97:517–22.

    Article  CAS  PubMed  Google Scholar 

  3. Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015;103:870–3.

    Article  CAS  PubMed  Google Scholar 

  4. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255–66.

    Article  CAS  PubMed  Google Scholar 

  5. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 1995;80:1967–71.

    CAS  PubMed  Google Scholar 

  6. Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JWT, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer. 2002;33:295–303.

    Article  CAS  PubMed  Google Scholar 

  7. Delvigne A. Epidemiology of OHSS. Reprod BioMed Online. 2009;19:8–13.

    Article  PubMed  Google Scholar 

  8. Berkkanoglu M, Coetzee K, Bulut H, Ozgur K. Risk of ovarian torsion is reduced in GnRH agonist triggered freeze-all cycles: a retrospective cohort study. J Obstet Gynaecol. 2018:1–6. https://doi.org/10.1080/01443615.2018.1479381.

  9. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril. 2011;95:2029–33.

    Article  CAS  PubMed  Google Scholar 

  10. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008–11.

    Article  CAS  PubMed  Google Scholar 

  11. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod BioMed Online. 2014;29:541–4.

    Article  PubMed  Google Scholar 

  12. Ling S-Y, Chong K-M, Hwang J-L. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome. Taiwan J Obstet Gynecol. 2006;45:70–2.

    Article  PubMed  Google Scholar 

  13. Santos-Ribeiro S, Polyzos NP, Stouffs K, de Vos M, Seneca S, Tournaye H, et al. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition. J Assist Reprod Genet. 2015;32:1063–8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Montanelli L, Delbaere A, Di Carlo C, et al. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2004;89:1255–8.

    Article  PubMed  Google Scholar 

  15. Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17:813–28.

    Article  CAS  PubMed  Google Scholar 

  16. Lledo B, Ortiz JA, Llacer J, Bernabeu R. Pharmacogenetics of ovarian response. Pharmacogenomics. 2014;15:885–93.

    Article  CAS  PubMed  Google Scholar 

  17. Boudjenah R, Molina-Gomes D, Torre A, Boitrelle F, Taieb S, Dos Santos E, et al. Associations between individual and combined polymorphisms of the TNF and VEGF genes and the embryo implantation rate in patients undergoing in vitro fertilization (IVF) programs. PLoS One. 2014;9:e108287.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Boudjenah R, Molina-Gomes D, Torre A, Bergere M, Bailly M, Boitrelle F, et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PLoS One. 2012;7:e38700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Morón FJ, de Castro F, Royo JL, Montoro L, Mira E, Sáez ME, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006;16:485–95.

    Article  CAS  PubMed  Google Scholar 

  20. O’Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol. 2013;11:71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19:14–27.

    Article  CAS  PubMed  Google Scholar 

  22. Mattassi R, Manara E, Colombo PG, Manara S, Porcella A, Bruno G, et al. Variant discovery in patients with Mendelian vascular anomalies by next-generation sequencing and their use in patient clinical management. J Vasc Surg. 2018;67:922–932.e11.

    Article  PubMed  Google Scholar 

  23. Hsu C-C, Chiang C-W, Cheng H-C, Chang WT, Chou CY, Tsai HW, et al. Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene. 2011;30:654–67.

    Article  CAS  PubMed  Google Scholar 

  24. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321–33.

    Article  CAS  PubMed  Google Scholar 

  25. Gómez R, Simón C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability1. Biol Reprod. 2003;68:2164–71.

    Article  CAS  PubMed  Google Scholar 

  26. Bahram F, Claesson-Welsh L. VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiol Off J Int Soc Pathophysiol. 2010;17:253–61.

    CAS  Google Scholar 

  27. Heinolainen K, Karaman S, D'Amico G, Tammela T, Sormunen R, Eklund L, et al. VEGFR3 modulates vascular permeability by controlling VEGF/VEGFR2 signaling. Circ Res. 2017;120:1414–25.

    Article  CAS  PubMed  Google Scholar 

  28. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199–205.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank the lab technicians of the Center for Medical Genetics for performing WES and Sanger sequencing. Funding was received from ‘Wetenschappelijk Fonds Willy Gepts of the UZ Brussel’.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katrien Stouffs.

Ethics declarations

Approval for the study was received from the Ethics Committee of the UZ Brussel (EC2916/67).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stouffs, K., Daelemans, S., Santos-Ribeiro, S. et al. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. J Assist Reprod Genet 36, 491–497 (2019). https://doi.org/10.1007/s10815-018-1372-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-018-1372-5

Keywords

  • OHSS
  • FLT4
  • Genetic predisposition
  • VEGFR3